Xenobese 120 is indicated for the treatment of obesity.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Consuming alcohol with Xenobese 120 does not cause any harmful side effects.
Xenobese 120 is highly unsafe to use during pregnancy. Seek your doctor's advice as studies on pregnant women and animals have shown significant harmful effects to the developing baby.
Xenobese 120 is safe to use during breastfeeding. Human studies suggest that the drug does not pass into the breastmilk in significant amounts and is not harmful to the baby. However, use only if prescribed by a doctor.
Xenobese 120 does not usually affect your ability to drive.
Xenobese 120 is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Xenobese 120 may not be needed in these patients. However, use caution as the medicine may be associated with the formation of kidney stones in patients with underlying kidney disease.
Xenobese 120 is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Xenobese 120 may not be needed in these patients. However, consult your doctor before use.
Common gastrointestinal side effects include oily spotting from the rectum, flatulence, fecal urgency, oily or fatty stool, abdominal discomfort, etc. Rare side effects may include influenza, anxiety, headache, fatigue, and hypersensitivity reactions such as pruritus, exanthema, urticaria, angioedema, and anaphylaxis.
Xenobese 120 is a lipase inhibitor that works in the stomach and small intestine by blocking the absorption of fat from food.
Orlistat is a potent, specific, and long-acting lipase inhibitor. It exerts its therapeutic activity in the lumen of the stomach and upper small intestine by forming a covalent bond with the active serine site of gastric and pancreatic lipases. The inactivated enzyme is thus rendered unable to hydrolyze dietary fats in the form of triglycerides into absorbable free fatty acids and monoglycerides. As undigested triglycerides cannot be absorbed, a caloric deficit arises which has a positive effect on weight control. Systemic absorption of orlistat is therefore not needed for the activity. At the recommended therapeutic dose of 120 mg three times a day, orlistat inhibits dietary fat absorption by approximately 30%.
The recommended dose of Orlistat is one 120 mg capsule to be taken immediately before, during, or up to one hour after each main meal. If a meal is missed or contains no fat, the dose of Orlistat should be omitted. Doses of Orlistat above 120 mg three times daily have not been shown to provide additional benefits. The effect of Orlistat results in an increase in fecal fat 24-48 hours after dosing. Upon discontinuation of therapy, fecal fat content usually returns to pretreatment levels within 48-72 hours.
Administration:
Single doses of 800 mg Adiponil and multiple doses of up to 400 mg three times a day for 15 days have been studied in normal-weight and obese subjects without significant adverse findings. Should a significant overdose of Adiponil occur, it is recommended that the patient be observed for 24 hours. Based on human and animal studies, systemic effects attributable to the lipase-inhibiting properties of Adiponil should be rapidly reversible.
Reduction in cyclosporine plasma levels when Adiponil was coadministered with cyclosporine. Adiponil inhibited the absorption of a vitamin E acetate supplement. The effect of Adiponil on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known. Hypothyroidism has been reported in patients treated concomitantly with Adiponil and levothyroxine. Patients treated concomitantly with Adiponil and levothyroxine should be monitored for changes in thyroid function. Administer levothyroxine and Adiponil at least 4 hours apart. Vitamin K absorption may be decreased with Adiponil. Patients on chronic stable doses of warfarin who are prescribed Adiponil should be monitored closely for changes in coagulation parameters. Convulsions have been reported in patients treated concomitantly with Adiponil and antiepileptic drugs. Patients should be monitored for possible changes in the frequency and/or severity of convulsions.
Chronic malabsorption syndrome, cholestasis, lactation.
Orlistat is a Pregnancy Category X drug and is contraindicated during pregnancy. Caution should be exercised when Orlistat is administered to a nursing woman.
Organic causes of obesity (e.g., hypothyroidism) should be excluded before prescribing Adiponil. Adiponil and cyclosporine should not be coadministered. Cyclosporine should be taken at least 2 hours before or after Adiponil in patients taking both drugs. Cyclosporine levels should be measured and frequently monitored. The decrease in body weight with Adiponil therapy may be less in type II diabetic patients than in non-diabetic patients. Antidiabetic drug treatment should be closely monitored during Adiponil therapy. Patients should be advised to adhere to the dietary recommendations. The daily intake of fat should be distributed between three main meals. Patients should be strongly encouraged to take a multivitamin supplement that contains fat-soluble vitamins to ensure adequate nutrition. The probability of the occurrence of gastrointestinal side effects may increase when Adiponil is taken with a fatty meal.
Store in a cool & dry place below 30°C, protect from light & moisture. Keep out of reach of children.
Q:
Q:
Q:
Q:
Q:
Q:
Q:
Q:
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.